Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection

Trial Profile

Pharmacokinetics of a Single-Dose of Dalbavancin in Preterm Neonates to Infants Ages 3 Months With Suspected or Confirmed Bacterial Infection

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Jul 2017

At a glance

  • Drugs Dalbavancin (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Durata Therapeutics
  • Most Recent Events

    • 03 Jul 2017 Planned number of patients changed from 24 to 12.
    • 03 Jul 2017 Planned End Date changed from 1 May 2017 to 1 May 2020.
    • 03 Jul 2017 Planned primary completion date changed from 1 May 2017 to 1 May 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top